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Aims The mammalian silent information regulator-two 1 (Sirt1) blunts the noxious effects of cardiovascular risk factors
such as type 2 diabetes mellitus and obesity. Nevertheless, the role of Sirt1 in regulating the expression of tissue
factor (TF), the key trigger of coagulation, and arterial thrombus formation remains unknown.
Methods
and results
Human as well as mouse cell lines were used for in vitro experiments, and C57Bl/6 mice for in vivo procedures. Sirt1
inhibition by splitomicin or sirtinol enhanced cytokine-induced endothelial TF protein expression as well as surface
activity, while TF pathway inhibitor protein expression did not change. Sirt1 inhibition further enhanced TF mRNA
expression, TF promoter activity, and nuclear translocation as well as DNA binding of the p65 subunit of nuclear
factor-kappa B (NFkB/p65). Sirt1 siRNA enhanced TF protein and mRNA expression, and this effect was reduced
in NFkB/p652/2 mouse embryonic fibroblasts reconstituted with non-acetylatable Lys310-mutant NFkB/p65. Acti-
vation of the mitogen-activated protein kinases p38, c-Jun NH2-terminal kinase, and p44/42 (ERK) remained unaf-
fected. In vivo, mice treated with the Sirt1 inhibitor splitomicin exhibited enhanced TF activity in the arterial vessel
wall and accelerated carotid artery thrombus formation in a photochemical injury model.
Conclusion We provide pharmacological and genetic evidence that Sirt1 inhibition enhances TF expression and activity by
increasing NFkB/p65 activation in human endothelial cells. Furthermore, Sirt1 inhibition induces arterial thrombus
formation in vivo. Hence, modulation of Sirt1 may offer novel therapeutic options for targeting thrombosis.
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1. Introduction
Cardiovascular diseases represent a major health burden. Acute vas-
cular events such as myocardial infarction and ischaemic stroke
account for the majority of deaths in Western countries.1 Formation
of an arterial thrombus is the central event in such acute vascular syn-
dromes. Tissue factor (TF) is the key trigger of the coagulation
cascade and thereby crucially involved in arterial thrombosis.2 –4 Its
impact on thrombus formation may be enhanced in atherosclerosis
since TF expression is induced in the inflammatory environment of
atherosclerotic plaques.5 In line with this notion, clinical studies
demonstrate higher TF levels in the culprit lesion of patients with
acute coronary syndromes.6 Numerous inflammatory mediators
such as tumour necrosis factor alpha (TNF-a7) or histamine,8 but
also pro-thrombotic mediators like thrombin,9 induce endothelial
TF expression by activating the MAP kinases p38, ERK, and c-Jun
NH2-terminal kinase (JNK), and consequently transcription factors
such as nuclear factor-kappa B (NFkB).2
Silent information regulator-two (Sir2) is an NAD+-dependent
class III histone deacetylase.10 The mammalian sirtuins are evolutiona-
rily conserved homologues of the yeast Sir2,11 and silent information
regulator-two 1 (Sirt1) is the closest orthologue.12 In addition to
maintaining chromatin structure,10 Sirt1 has been shown to regulate
transcription factors such as forkhead box class O (FOXO),13
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p53,14 peroxisome proliferator-activated receptor-g,15 endothelial
nitric oxide synthase (eNOS),16 and p65 subunit of nuclear factor-
kappa B (NFkB/p65).17 Hence, Sirt1 is critically involved in cellular
responses to stress,18 senescence,19 and mitochondrial function.20
Furthermore, endothelial overexpression of Sirt1 diminishes plaque
formation in a mouse model of atherosclerosis,21 and pharmacological
activation of Sirt1 improves glucose homeostasis in mice and
humans.22 Based on these findings, Sirt1 modulators are under inves-
tigation in clinical trials for the treatment of patients with cardiovascu-
lar risk factors.
Since downstream targets of Sirt1 such as NFkB are involved in the
regulation of TF expression, this study was designed to investigate the
effect of Sirt1 on TF expression and arterial thrombus formation.
2. Methods
2.1 Cell culture
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland)
were cultured as described.23 Briefly, adhering HAECs were grown to con-
fluence and rendered quiescent for 24 h in medium containing 0.5% FCS
before stimulation. Sirt12/2 mouse embryonic fibroblasts (MEFs) were
kindly provided by David Sinclair (Harvard Medical School, Boston, MA,
USA) and were grown to confluence in Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS. Similarly, NFkB/p652/2 MEFs with
reconstituted wild-type NFkB/p65 or non-acetylatable Lys310-mutant
NFkB/p65 were used as described previously.24 Cells were pre-treated
with splitomicin (Sigma, Buchs, Switzerland), sirtinol (Calbiochem,
Lucerne, Switzerland), or resveratrol (Sigma) for 1 h before stimulation
with 5 or 10 ng/mL TNF-a (R&D Systems, Minneapolis, MN, USA), 1 U/
mL thrombin (R&D Systems), or 1025 mol/L histamine (Sigma), respect-
ively. Transient transfection with pcDNA3.1-SIRT1 or Sirt1 siRNA (Sirt1
siRNA oligonucleotide sequence: 5′-GATGAAGTTGACCTCCTCA-3′)
was performed using Lipofectamine Reagent (Invitrogen, Basel, Switzer-
land) or Lipofectamine RNAi MAX (Invitrogen), respectively, as described
previously.15,25 Cytotoxicity was assessed by a colorimetric assay to detect
lactate dehydrogenase (LDH; Roche, Basel, Switzerland).
2.2 Western blot analysis
Protein expression was determined as described.8 Antibodies against
human TF, tissue factor pathway inhibitor (TFPI; both from American
Diagnostica, Stamford, CT, USA), and Sirt1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used at 1:2000 dilution. Antibodies against
phosphorylated p38 mitogen-activated protein (MAP) kinase (p38), p44/
42 MAP kinase (ERK), and JNK (all from Cell Signaling, Danvers, MA,
USA) were used at 1:1000, 1:5000, and 1:1000 dilution, respectively. Anti-
bodies against total p38, ERK, and JNK (all from Cell Signaling) were
diluted to 1:3000, 1:10 000, and 1:1000, respectively. The antibody
against IkB-a (Santa Cruz Biotechnology) was applied at a 1:1000 dilution.
Alpha-tubulin (Sigma) were applied to control protein loading (1:10 000
dilution). Primary antibodies were detected with a horseradish
peroxidase-linked secondary antibody (Amersham, Munich, Germany).
2.3 Real-time PCR
Total RNA was extracted from HAECs with 1 mL TRIzol Reagent (Invi-
trogen) as described.23 Conversion of total cellular RNA to cDNA was
carried out with Moloney murine leukaemia virus reverse transcriptase
and random hexamer primers (Amersham) in a final volume of 33 mL
using 4 mg of RNA. The total cDNA pool obtained served as template
for subsequent PCR amplification with primers specific for full-length
TF (sense primer: 5′-TCCCCAGAGTTCACACCTTACC-3′ , antisense
primer: 5′-CCTTTCTCCTGGCCCATACAC-3′; bases 508–529 of F3
cDNA; NCBI no. NM 001993). Real-time PCR amplification was
performed in an MX3000P PCR cycler (Stratagene) using the SYBR
Green JumpStart kit (Sigma) in 25 mL final reaction volume containing
2 mL cDNA, 10 pmol of each primer, 0.25 mL of internal reference dye,
and 12.5 mL of JumpStart Taq ReadyMix (buffer, dNTP, stabilizers, SYBR
Green, Taq polymerase, and JumpStart Taq antibody). A melting curve
analysis was performed after amplification to verify the accuracy of the
amplicon. Ribosomal L28 RNA in HAECs or S12 RNA in MEFs served
as loading control.
2.4 TF activity in vitro
TF surface activity in HAECs was analysed using a colorimetric assay
(American Diagnostica). Cells were incubated at 378C with human FVIIa
and FX, allowing for the formation of the TF/FVIIa complex at the cell
surface. Conversion of FX to FXa was measured by the ability of FXa
to cleave a chromogenic substrate. A standard curve was established
with lipidated human TF to assure that the results were in the linear
range of detection.
2.5 Histone deacetylase activity
Cell-based histone deacetylase activity (HDAC) assay was performed
according to the manufacturer’s instructions (BIOMOL, Hamburg,
Germany). Briefly, HAECs were starved in phenol-red-free media contain-
ing 0.5% FCS. After 24 h, cells were incubated with 200 mmol/L Fluor de
Lys substrate with or without trichostatin A (TSA; 1 mmol/L, BIOMOL),
and with or without splitomicin (100 mmol/L, Sigma). After 2 h, cells
were incubated with Fluor de Lys developer, lysed after 30 min, and
equal amount of lysates were analysed for enzyme activity using a fluor-
escence reader (Ex. 360 nm, Em. 460 nm).
2.6 TF promoter activity
An adenoviral vector (Ad5/hTF/Luc) containing the minimal TF promoter
(2227 to +121 bp) upstream of the Luciferase cDNA and the SV40
PolyA signal was prepared as described.26 For viral transfection, the
vector was added to HAEC at 100 pfu/cell for 1 h. HAEC were kept in
growth medium for 24 h and then serum-starved for 24 h prior to
TNF-a stimulation with or without Sirt1 inhibitor pre-treatment. Cells
were stimulated with TNF-a for 30 min. Firefly luciferase activity was
determined in cell lysates using a luminometer (Bertholg Technologies,
Bad Wildbad, Germany).
2.7 NFkB DNA binding assay and NFkB/p65
immunofluorescence
Adhering HAECs were pre-treated with Sirt1 inhibitors for 1 h, followed
by stimulation with 10 ng/mL TNF-a for additional 30 min. Nuclear
protein was obtained by using a nuclear extraction kit (Active Motif, Rix-
ensart, Belgium). Cells were harvested in hypotonic buffer for 15 min
before centrifugation, isolated nuclei were resuspended in a hypertonic
buffer, and nuclear protein was extracted by incubation on a rotator
for 30 min. The supernatant containing the nuclear protein was collected
after centrifugation. The DNA binding reaction was carried out with 5 mg
of nuclear protein in a 96-well plate coated with consensus sequences for
NFkB (GGGACTTTCC) for 1 h at room temperature. After washing,
NFkB/p65 antibody (Active Motif) was added and incubated for 1 h, fol-
lowed by incubation with a horseradish peroxidase-conjugated secondary
antibody. Finally, NFkB/p65 DNA binding was assessed spectrophotome-
trically at 450 nm.
HAECs were stained with FITC-labelled mouse anti-NFkB/p65 (Santa
Cruz Biotechnology). Cytoplasmic NFkB/p65 was analysed using an SP2
confocal microscope (Leica), and quantification performed with the open-
source software CellProfiler.27 Intensity of the green channel was
measured in the cytoplasm (nuclear area subtracted from the total cell
area) of at least 150 cells per treatment group at the Z-section where
the nuclei had their largest diameter.
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2.8 NFkB/p65 immunoprecipitation
HAECs were treated with 50 mM SIRT1 or scrambled siRNA overnight,
followed by stimulation with TNF-a (10 ng/mL) for 20 min. Cells were
then harvested and protein extracted in lysis buffer (20 mM HEPES, pH
7.5, 80 mM NaCl, 2.5 mM MgCl2, 1 mM EDTA, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride, 10 mg/mL aprotinin, 10 mg/mL leupeptin, and
100 mM splitomicin). One milligram whole-cell lysates were immunopre-
cipitated with rabbit anti-NFkB/p65 (Santa Cruz) using Protein G agarose
(Millipore, Zug, Switzerland). Immunoprecipitated samples were immuno-
blotted with rabbit anti-acLys310 NFkB/p65 (Abcam, Cambridge, UK), the
total lysates (5% input) with rabbit anti-SIRT1 and rabbit anti-NFkB/p65
(both from Santa Cruz Biotechnology).
2.9 Carotid artery thrombosis model and TF
activity in vivo
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication
no. 85-23, revised 1996). All animal procedures were approved by the
local animal committee (Kantonales Veterina¨ramt Zurich, Switzerland)
and performed in accordance with our institutional guidelines. C57BL/6
mice aged 12–14 weeks weighing on average 27 g were anaesthetized
by intraperitoneal injection of 87 mg/kg sodium pentobarbital (Butler,
Columbus, OH, USA). Rose Bengal (Fisher Scientific, Fair Lawn, NJ,
USA) was diluted to 12 mg/mL in phosphate-buffered saline and then
injected into the tail vein at a concentration of 63 mg/kg. Mice were
secured in a supine position, placed under a dissecting microscope, and
the right common carotid artery was exposed following a midline cervical
incision. A Doppler flow probe (Model 0.5 VB, Transonic Systems, Ithaca,
NY, USA) was applied and connected to a flowmeter (Transonic, Model
T106). Six minutes after Rose Bengal injection, a 1.5 mW green light
laser (540 nm; Melles Griot, Carlsbad, CA, USA) was applied to the site
of injury at a distance of 6 cm for 60 min or until thrombosis occurred.
From the onset of injury, blood flow was monitored up to 120 min, at
which time the experiment was terminated.7 Occlusion was defined as
flow ≤0.1 mL/min for at least 1 min. Mice were divided into two
groups: splitomicin (80 mg/kg with an intraperitoneal injection every
24 h for 5 days), or vehicle control (0.5% methylcellulose).
Right carotid arteries were homogenized in 50 mL of lysis buffer and left
to stand on ice for 30 min. TF activity was measured by using the colori-
metric assay as described above.
2.10 Statistical analysis
Data are indicated as mean+ SEM. Unpaired Student’s t-test was used to
evaluate differences between two groups. For statistical analysis of data
from multiple groups, one-way ANOVA was performed. A P value
,0.05 denoted a significant difference. All statistical values are additionally
summarized in the Supplementary material online, Table S1.
3. Results
3.1 Sirt1 inhibition enhances TF expression
and activity
TF protein expression was determined in TNF-a (5 ng/mL for 5 h)
stimulated HAECs in the presence or absence of increasing concen-
trations of splitomicin (25–200 mmol/L) or sirtinol (15–60 mmol/L),
respectively. Both inhibitors enhanced TNF-a-induced TF protein
expression in a concentration-dependent manner; maximal activation
occurred at 100 mmol/L in splitomicin and at 30 mmol/L in sirtinol-
treated cells, respectively (n ¼ 4; P, 0.05; Figure 1A and C ). These
effects were paralleled by an increased TF surface activity in cells pre-
treated with either Sirt1 inhibitor (n ¼ 4; P, 0.01, Figure 1B and D).
Sirt1 knockdown using specific siRNA enhanced TNF-a-induced TF
protein expression (n ¼ 4; P, 0.01; Figure 1E); western blot analysis
confirmed reduced Sirt1 expression in cells transfected with Sirt1
siRNA (n ¼ 4; P, 0.01; Figure 1F). Sirt1 inhibition also enhanced TF
protein expression in response to stimulation with histamine
(1025 mol/L) or thrombin (1 U/mL), respectively (n ¼ 4; P, 0.05;
Figure 2A). The expression of TFPI, the physiological antagonist of
TF, remained unaffected (n ¼ 4; P ¼ NS; Figure 2B). TNF-a did not
alter endogenous Sirt1 protein expression (n ¼ 4; P ¼ NS;
Figure 2C), and no changes in cell morphology nor LDH release
were detected by any of these treatments (n ¼ 4 for each; P ¼ NS;
Supplementary material online, Figure S1).
3.2 TF mRNA expression is induced
by Sirt1 inhibition
Real-time rtPCR revealed that TNF-a (5 ng/mL) induced TF mRNA
expression within 1 h (n ¼ 4; P, 0.05; Figure 3A). Both splitomicin
and sirtinol enhanced TF mRNA expression in stimulated endothelial
cells (splitomicin: n ¼ 4; P, 0.05; Figure 3A, sirtinol: n ¼ 4; P, 0.05;
Figure 3B). In parallel, Sirt1 knockdown using siRNA enhanced
TNF-a-stimulated TF mRNA expression (n ¼ 4; P, 0.01; Figure 3C).
3.3 Sirt1 inhibition reduces HDAC
class III activity
A cell-based HDAC assay was performed in HAECs to confirm that
the Sirt1 inhibitor splitomicin diminishes intracellular deacetylase
activity. Cells were treated with 1 mmol/L TSA to inactivate HDAC
classes I and II in the presence or absence of splitomicin
(100 mmol/L). Consistent with inhibition of HDAC class III, splitomicin
reduced deacetylase activity (n ¼ 4; P, 0.05; Supplementary material
online, Figure S2A) as compared with TSA alone. In contrast, splitomi-
cin did not affect TF protein expression in Sirt12/2 MEFs (n ¼ 4; P ¼
NS; Supplementary material online, Figure S2B).
3.4 Activation of Sirt1 impairs TF
expression and activity
Pharmacological activation of Sirt1 by resveratrol, a commonly used,
but less specific Sirt1 activator, impaired TNF-a-induced TF protein
and mRNA expression (n ¼ 4; P, 0.01 for TF protein, and P,
0.05 for TF mRNA; Supplementary material online, Figure S3A and
B). In parallel, overexpression of Sirt1 in Sirt12/2 MEFs reduced
TNF-a-induced TF expression (n ¼ 4; P, 0.01; Supplementary
material online, Figure S3C and D).
3.5 Sirt1 inhibition enhances TF promoter
activity
To assess whether Sirt1 inhibition enhances TF promoter activity, the
impact of splitomicin and sirtinol on the TF promoter was analysed.
HAECs were transfected with a luciferase plasmid under control of
the human minimal TF promoter (2221 up to +121 bp). Splitomicin
and sirtinol enhanced stimulated TF promoter activity as compared
with TNF-a alone (n ¼ 5; P, 0.01; Figure 4A and B).
3.6 MAP kinase activation is not affected by
Sirt1 inhibition
To assess whether modulation of Sirt1 activity alters MAP kinase acti-
vation, HAECs were examined at different time points after TNF-a
stimulation. The MAP kinases p38, ERK, and JNK were transiently
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Figure 1 Sirt1 inhibition enhances endothelial TF expression and activity. (A and B) Splitomicin enhances TNF-a-induced TF protein expression
(*P, 0.05 vs. TNF-a alone) and surface activity (*P, 0.01 vs. TNF-a alone) in human endothelial cells. (C and D) Sirtinol exerts similar effects
on TF protein expression (*P, 0.05 vs. TNF-a alone) and activity (*P, 0.01 vs. TNF-a alone). (E and F) Sirt1 siRNA enhances TNF-a-induced
TF protein expression (*P, 0.01 vs. TNF-a alone).
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activated by TNF-a (n ¼ 3; Supplementary material online, Figures S4
and S5). Phosphorylation of p38, ERK, and JNK remained unaffected in
cells pre-treated with either splitomicin (n ¼ 3; P ¼ NS; Supplemen-
tary material online, Figure S4) or sirtinol, respectively (n ¼ 3; P ¼
NS; Supplementary material online, Figure S5). Total expression of
MAP kinases remained unchanged at any time point with or
without Sirt1 inhibitors.
3.7 Sirt1 inhibition enhances NFkB/p65
DNA binding via deacetylation of Lys310
of NFkB/p65
NFkB/p65 is a transcription factor that regulates TF expression. Thus,
the effect of Sirt1 inhibition on NFkB/p65 activation was investigated.
TNF-a (10 ng/mL) induced a significant increase in NFkB/p65 DNA
binding as compared with control (n ¼ 5; P, 0.01; Figure 5A and
B). Sirt1 inhibition with splitomicin (100 mmol/L) or sirtinol
(30 mmol/L) enhanced NFkB/p65 DNA binding (n ¼ 5; P, 0.01;
Figure 5A and B). In line with this, translocation of NFkB/p65 from
the cytoplasm to the nucleus was increased after TNF-a stimulation
as confirmed by NFkB/p65 immunofluorescence and pre-treatment
with splitomicin further enhanced NFkB/p65 nuclear translocation
(n ¼ 5; P, 0.01; Supplementary material online, Figure S6).
Since degradation of the inhibitory protein of NFkB, IkB-a, is an
early step in activation of NFkB/p65, the effect of Sirt1 inhibition on
IkB-a degradation was investigated. TNF-a induced a transient degra-
dation of IkB-a (n ¼ 3; Supplementary material online, Figures S4 and
S5). Neither splitomicin nor sirtinol altered the degradation pattern of
IkB-a as compared with TNF-a alone (n ¼ 3; P ¼ NS; Supplementary
material online, Figures S4 and S5).
For further analysis, NFkB/p652/2 MEFs were used and reconsti-
tuted with either wild-type NFkB/p65 or a non-acetylatable Lys310-
mutant NFkB/p65. The effect of Sirt1 siRNA on TF expression was
less pronounced in MEFs reconstituted with the non-acetylatable
Lys310-mutant NFkB/p65 as compared with the wild-type NFkB/p65
(n ¼ 5; P, 0.01; Figure 5C), although both types of reconstituted
cells exhibited enhanced TF mRNA expression after TNF-a stimulation
when Sirt1 was knocked down by siRNA (n ¼ 5; P, 0.05; Figure 5C).
Western blot analysis confirmed reduced Sirt1 expression in all the
cells transfected with Sirt1 siRNA (n ¼ 4; P, 0.05; Figure 5D).
Sirt1 was also silenced in HAECs using siRNA. The cells were
stimulated with TNF-a (10 ng/mL) and a NFkB/p65
Figure 2 Splitomicin induce TF expression in response to different mediators, but does not alter TFPI expression. TNF-a does not alter Sirt1
expression. (A) TNF-a, histamine, and thrombin induce TF protein expression. Splitomicin up-regulates TF expression in response to each stimulus
(*P, 0.05 vs. each stimulation factor). (B) Splitomicin does not alter TFPI expression (P ¼ NS). (C) TNF-a stimulation does not change endogenous
expression of Sirt1 (P ¼ NS).
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immunoprecipitation was performed. There was a higher extent of
Lys310 NFkB/p65 acetylation in cells with impaired Sirt1 expression
(n ¼ 3; Figure 5E).
3.8 Sirt1 inhibition induces TF activity and
arterial thrombosis in vivo
C57Bl/6 mice were treated with splitomicin (80 mg/kg body weight,
intraperitoneal injection every 24 h for 5 days) or vehicle (0.5%
methylcellulose). Vehicle-treated mice developed carotid artery
thrombosis within a mean occlusion time of 57.8.+7.5 min, while
splitomicin-treated mice occluded within a mean time period of
31.2+5.3 min (n ¼ 7; P, 0.05; Figure 6A). Initial blood flow in
carotid artery did not differ between vehicle- and splitomicin-treated
mice (0.54+0.05 vs. 0.52+0.05 mL/min; n ¼ 7; P ¼ NS; Figure 6B).
Splitomicin treatment increased TF activity in mouse carotid artery
in vivo as compared with the controls (n ¼ 6; P, 0.05; Figure 6C).
Figure 3 Sirt1 inhibition induces endothelial TF expression at the
transcriptional level. (A and B) Real-time rtPCR reveals that splitomi-
cin and sirtinol enhance TNF-a-induced TF mRNA expression
(*P, 0.05 vs. TNF-a alone for splitomicin; *P, 0.05 vs. TNF-a
alone for sirtinol). (C) Sirt1 siRNA enhances TNF-a-induced TF
mRNA expression (*P, 0.01 vs. TNF-a alone).
Figure 4 Sirt1 inhibition increases TF promoter activity. (A and B)
TNF-a increases the activity of the minimal TF promoter. Splitomicin
(A) and sirtinol (B) enhance TF promoter activity under
cytokine-induced conditions (*P, 0.01 vs. TNF-a alone). AU, arbi-
trary units.
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4. Discussion
The present study demonstrates that Sirt1 inhibits TF expression at the
transcriptional level via NFkB/p65 in human vascular cells. Further-
more, it shows that inhibition of Sirt1 induces thrombus formation
and arterial TF activity in vivo.
To inhibit Sirt1 activity in human vascular cells, two different
pharmacological agents were applied. Both splitomicin and sirtinol
are established inhibitors of Sirt1.11,28– 30 It is still debated to what
extent these drugs specifically inhibit Sirt1; indeed, sirtinol may also
inhibit Sirt2.30 Nevertheless, the concentrations of both substances
applied in this study are within the established range.17,19 Moreover,
splitomicin did not alter TF expression in Sirt12/2 MEFs, and TF
was increased when Sirt1 was down-regulated by siRNA. Hence,
these data support the conclusion that Sirt1 regulates the expression
of TF.
Cytokine-mediated TF expression is mainly regulated at the tran-
scriptional level, where NFkB/p65 is importantly involved.2 Transcrip-
tionally active NFkB consists of a heterodimeric complex mainly
composed of a p65 and a p50 subunit. In quiescent cells, NFkB is
retained in the cytoplasm by its inhibitor IkB. Upon cytokine stimu-
lation, IkB becomes degraded allowing NFkB to translocate to the
nucleus and to stimulate gene transcription. In this study, both Sirt1
inhibitors enhanced nuclear translocation and DNA binding of NFkB/
p65, identifying NFkB/p65 as a downstream target of Sirt1 in the
context of TF expression. Since the Sirt1 inhibitors did not affect
MAP kinases nor IkB degradation, an involvement of these mediators
can be ruled out; thus, a direct effect of Sirt1 on NFkB/p65 seems
Figure 5 Sirt1 inhibition enhances NFkB/p65 activation via acetylation of Lys310 of NFkB/p65. (A and B) TNF-a stimulates NFkB/p65 DNA binding
activity as compared with control conditions. Splitomicin and sirtinol both enhance NFkB/p65 DNA binding (*P, 0.01 vs. TNF-a alone). (C) Sirt1
siRNA induces TF mRNA up-regulation in the presence of wild-type NFkB/p65, whereas its expression is reduced by a non-acetylatable Lys310-mutant
NFkB/p65 (*P, 0.01 vs. wild-type NFkB/p65). (D) Sirt1 protein down-regulation by specific siRNA is demonstrated. (E) NFkB/p65 immunoprecipita-
tion in HAECs reveals more acetylated Lys310 NFkB/p65 upon Sirt1 siRNA treatment.
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likely. Acetylation of Lys310 and Lys221 residues of NFkB/p65 impairs its
association with IkB and increases its DNA-binding capacity.31 Sirt1
deacetylates Lys310 of the NFkB/p65 subunit in different cell types
and thereby blunts NFkB/p65-mediated gene expression.17,32 Exper-
iments involving NFkB/p652/2 MEFs reconstituted with either wild-
type NFkB/p65 or non-acetylatable Lys310-mutant NFkB/p65, respect-
ively, demonstrate that regulation of TF mRNA expression by Sirt1
indeed depends on Lys310 acetylation of NFkB/p65. Nevertheless,
other downstream targets of Sirt1, such as eNOS or p53, are also
known to regulate TF expression,33,34 and a role of these regulators
in Sirt1-mediated TF expression in addition to that of NFkB/p65
cannot be ruled out by the current data.
TF is the key initiator of coagulation and therefore an important
trigger of thrombosis.35 Exposure of TF to the circulating blood
results in acute thrombosis and eventually vascular occlusion; in
fact, reducing TF expression impairs thrombus formation.36 To inves-
tigate arterial thrombosis in vivo, a photochemical vascular injury
model was used, since it is an established method to study
TF-dependent thrombus formation.36 Mean occlusion time in
splitomicin-treated mice was reduced by nearly 50%, supporting the
concept that inhibition of Sirt1 induces arterial thrombosis. The
increased TF activity in mouse carotid artery indicates that Sirt1 inhi-
bition regulates thrombosis at least in part via activation of TF in vivo.
TFPI, the physiological inhibitor of TF, was not affected by splitomicin
treatment excluding compensatory effects on TF activity. Given the
importance of the balance between TF and TFPI for thrombosis,37
these findings underscore a role for TF in the modulation of thrombus
formation by Sirt1. Hence, Sirt1 activators, which are currently under
investigation for the treatment of type 2 diabetes mellitus, may
possess additional protective cardiovascular effects by inhibiting arter-
ial thrombus formation.
Sirt1 inhibition resulted in an enhanced TF expression after stimu-
lation with different mediators. Hence, Sirt1 may suppress TF
expression especially in the inflammatory environment observed in
patients exposed to cardiovascular risk factors and with advanced
atherosclerotic lesions.38 Indeed, elevated levels of soluble TF are
observed in patients with atherosclerosis as compared with con-
trols.39 Furthermore, even higher concentrations are measured in
the area around the culprit lesion in patients with unstable angina
or acute myocardial infarction as compared with patients with
stable angina.6,40 Taken together, pharmacological or genetic acti-
vation of Sirt1 could be a promising therapeutic target in these
conditions.
A recent report described that endothelial overexpression of Sirt1
diminishes atherogenesis in ApoE-deficient mice, suggesting an anti-
atherosclerotic effect of Sirt1.21 In addition, Sirt1 exerts beneficial
effects on cardiovascular risk factors such as type 2 diabetes mellitus
and arterial hypertension.22,41,42 Sirt1 also mediates the effects of
caloric restriction on life-span extension,43 which may in turn
improve endothelial function and blood pressure regulation.44 Since
TF expression and activity is increased by cardiovascular risk factors
such as type 2 diabetes mellitus45,46 and arterial hypertension,47
Sirt1 activators, which are currently under investigation in clinical
trials for the treatment of cardiovascular risk factors, could exert a
dual beneficial effect preventing arterial thrombosis not only by
down-regulating TF expression, but also by interfering with the risk
factors inducing it.
In summary, this study demonstrates that Sirt1 inhibition enhances
TF in vitro as well as in vivo, and accelerates arterial thrombus for-
mation. Sirt1 exerts these effects at the transcriptional level by mod-
ulating NFkB/p65 DNA binding without affecting MAP kinase
activation. These findings reveal a novel action of Sirt1 and suggest
that Sirt1 activators may be applied for the prevention of
thrombosis.
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